Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06499831 | 18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas(FETSMaRT) | unknown | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT01903330 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | unknown | Phase 2 | 84 | Epitopoietic Research CorporationINDUSTRY | 1 | Mar 5, 2025 |
| NCT06585527 | Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma | unknown | Phase 1 | 30 | Beijing Neurosurgical InstituteOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06353360 | TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 30 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06214689 | IDH1 and OCT4 in High Grade Astrocytoma | unknown | — | 35 | Assiut UniversityOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04007185 | Surgically Induced Neurological Deficits in Glioblastomas (SIND Study)(SIND) | unknown | — | 52 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05638451 | Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT02613988 | Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas | unknown | N/A | 100 | Asan Medical CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04600817 | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) | unknown | Phase 2 | 160 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 15, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT06348693 | Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness | unknown | — | 400 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05043701 | Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma(ISM-GBM) | unknown | Early Phase 1 | 15 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05163080 | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)(SURVIVE) | unknown | Phase 2 | 247 | MimiVax, LLCINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04530006 | Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma | unknown | N/A | 20 | CancerCare ManitobaOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05868083 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | unknown | Phase 1 | 16 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06241391 | Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas | unknown | N/A | 35 | All India Institute of Medical Sciences, BhubaneswarOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06196918 | Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients | unknown | N/A | 320 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04197492 | Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | unknown | Phase 2 | 22 | Huashan HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05328089 | Vacuolar ATPase and Drug Resistance of High Grade Gliomas(GLIODRUG-V) | unknown | — | 20 | University of Milano BicoccaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05820191 | B-amyloid as a Marker for GBM Bioimaging | unknown | Phase 2 | 3 | Universidad Central del CaribeOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03582514 | PreOperative Brain Irradiation in Glioblastoma(POBIG) | unknown | Phase 1 | 18 | The Christie NHS Foundation TrustOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03951142 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study(ImPRESS) | unknown | Phase 2 | 165 | Kyrre Eeg EmblemOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05235737 | The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab(PIRG) | unknown | Phase 4 | 36 | Medical University of SilesiaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05802693 | A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma | unknown | Early Phase 1 | 22 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT04532229 | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | unknown | Phase 3 | 48 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05958485 | A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04967690 | A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM(TARGLIO) | unknown | Phase 1 | 27 | Double Bond Pharmaceutical ABINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT05929456 | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)(MIRROR) | unknown | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04671459 | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine(TaRRGET) | unknown | Phase 2 | 40 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05191784 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 20 | Genexine, Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05728125 | Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT04223999 | Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)(OptimalTTF-2) | unknown | Phase 2 | 70 | Anders Rosendal KorshøjOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03411408 | Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.(HBO-RT) | unknown | N/A | 24 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05764460 | Social Cognition and Language in Patients With Gliomas | unknown | — | 105 | University Medical Center GroningenOTHER | 0 | May 17, 2023 | clinicaltrials |
| NCT05850377 | 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas | unknown | — | 90 | Sociedad de Lucha Contra el Cáncer del EcuadorOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02137759 | MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | unknown | Phase 2 | 29 | Emory UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04359745 | Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression | unknown | — | 500 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05363826 | Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac® | unknown | Phase 1 | 30 | Photolitec LLCINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05811793 | Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma. | unknown | N/A | 36 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Apr 13, 2023 | clinicaltrials |
| NCT05793021 | FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype | unknown | N/A | 70 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT01672463 | Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients(OKN-007) | unknown | Phase 1 | 31 | Oblato, Inc.INDUSTRY | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03561207 | 3D Prediction of Patient-Specific Response(3D-PREDICT) | unknown | — | 570 | KIYATECINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05772741 | Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs(2253) | unknown | N/A | 160 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05737368 | Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | unknown | Phase 1 | 11 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 21, 2023 | clinicaltrials |
| NCT04642937 | Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma | unknown | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Jan 27, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 25, 2025source: clinicaltrials